The Results of the Comparison between Olanzapine and One-Dose Dexamethasone and Four-Day Dexamethasone in Prevention of Chemotherapy induced Nausea and Vomiting in Patients with Pancreatic Cancer Receiving Modified FOLFIRINOX

Phase 2

• Conditions: Patients with pancreatic cancer plan to receive modified FOLFIRINOX chemotherapy regimen; chemotherapy-induced nausea and vomiting; modified FOLFIRINOX; pancreatic cancer; Olanzapine; dexamethasone

• Registration Number: TCTR20230307001
• Lead Sponsor: Hathaipat Veerawatananan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-07
• Study Completion: 2023-05-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: nknown
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

Eligible patients were 18 and 80 years old patients with Eastern Cooperative Oncology group (ECOG) performance status 0-1

Exclusion Criteria

preexisting nausea symptoms, inadequate organ function, allergy or contraindication to ondansetron, dexamethasone, olanzapine, cognitive compromise or having a history of dyskinesia, movement, CNS disorder or psychiatric disorder

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
complete response (CR) of vomiting (no vomiting) in the overall phase (0-120 hours) after start chemotherapy 0-120 hours after start chemotherapy rate of vomiting (no vomiting) in the overall phase

Secondary Outcome Measures

Name	Time	Method
CR of nausea (no nausea) in the overall phase 0-120 hours after start chemotherapy rate of nausea (no nausea) ,incidence of hyperglycemia during 2 chemotherapy sessions incidence of hyperglycemia